The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

Cerebral Infarction Clinical Trial

Official title:

The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01926834
• Other study ID #: 1201/01/006284
• Status: Not yet recruiting
• Phase: Phase 4
• First received: August 19, 2013
• Last updated: August 19, 2013
• Start date: August 2013
• Est. completion date: March 2014

Study information

• Verified date: August 2013
• Source: Guangzhou University of Traditional Chinese Medicine
• Contact: Jianwen Guo, doctor
• Phone: 0086-13724899379
• Email: jianwen_guo[@]msn.com
• Is FDA regulated: No
• Health authority: China: State Administration of Traditional Chinese Medicine of the People's Republic of China
• Study type: Interventional

Clinical Trial Summary

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction,test is made by random double-blind controlled.patients with acute cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin group,and health people. The main indexes are the serum level of VEGF, MMP-9 and EPC.The review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function of promoting angiogenesis in multiple targets through this test.

Description:

OBJECTIVE:

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction.

METHOD:

40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people. Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior treatment,the posttreatment 1th, 3th and 7th day,and tested the level of VEGF, MMP-9 and EPC.Tested the health people one time.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: March 2014
• Est. primary completion date: August 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients aged no younger than 18yrs

• attack within 72 hours

• NIHSS score in the 2-25 points

• Ischemic Stroke occurred for the first time, or with a history of stroke disease but without sequelae

• Signed the informed consents

Exclusion Criteria:

• patients aged younger than 18yrs

• Patients with tumor, coronary heart disease, valvular heart disease, psoriasis, rheumatism, hematologic diseases, infertility, varieties of acute inflammation

• Patients with severe cognitive impairment

• Refused to cooperate or been unable to cooperation for neurological disorders

• Cerebral hemorrhage or hemorrhagic cerebral infarction

• Unstable vital signs dued to massive cerebral infarction

• Patients with serious heart, liver and renal insufficiency

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cerebral Infarction
• Infarction

Intervention

Drug:
• Erigeron Injection
Erigeron Injection, 30ml, iv, qd, for 7days
• placebo
normal saline, 500ml,i.v.,qd, for 7 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou University of Traditional Chinese Medicine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the serum level of VEGF,MMP-9 and EPC		0-7days	No
Secondary	National Institute of Health of stroke scale		0-7days	No